19 Firstfield Road
About Altimmune, Inc.Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.
CEO: Bill Enright, MBA
Chief Scientific Officer: Scot Roberts, PhD
CFO: Elizabeth A. Czerepak
Chief Technology Officer: Bertrand Georges, PhD
21 articles with Altimmune, Inc.
$12 million underwritten public offering closed October 2 $4.9 million registered direct offering closed September 26
Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine
A statistically superior mucosal immune response providing a first line of defense against infection
The Company has already been granted patents extending IP protection for intranasal administration of NasoShield in Europe and Japan.
The Board’s current Chairman, David Drutz, M.D., will remain on as Chairman of the Compensation Committee and Member of the Board.
Altimmune today announced it has completed dosing of its HepTcell Phase 1 study in chronic hepatitis B.
Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase I Trial
145 Patients to be enrolled in the trial.
Conference call and webcast scheduled for Friday, November 10 at 8:30am ET.
Altimmune Submits Investigational New Drug Application For Nasovax In Preparation For Phase II Trial
Altimmune Completes Merger With PharmAthene, Inc. Creating Immunotherapeutics Company Targeting Infectious Diseases
PharmAthene, Inc. Announces Record Date And Meeting Date For Special Meeting Of Stockholders Regarding Proposed Merger Transaction With Altimmune
PharmAthene, Inc. Release: Company And Altimmune Announce Merger To Create Immunotherapeutics Company Targeting Infectious Diseases
Altimmune Receives BARDA Contract Of Up To $120.2 Million To Fund Clinical Development Of First-In-Class Anthrax Vaccine Candidate Nasoshield